NEW YORK, NY / ACCESSWIRE / September 27, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX). Investors who purchased SCYNEXIS securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/scyx.
The investigation concerns whether SCYNEXIS has violated federal securities laws.
Investigation Details:
On September 25, 2023, Scynexis announced a recall of its anti-fungal therapy ibrexafungerp and placing a temporary hold on its clinical studies due to the risk of a potential contaminant. The Company stated that the decision to recall follows an investigation that found the production of a contaminant called a beta-lactam drug substance during ibrexafungerp's manufacturing process. The non-antibacterial compound can lead to hypersensitivity or allergic reactions in some individuals. On this news, Scynexis's stock price fell $1.38 per share, or 41.69%, over the following two trading sessions, to close at $1.38 per share on September 26, 2023.
What's Next?
If you are aware of any facts relating to this investigation or purchased SCYNEXIS securities, you can assist this investigation by visiting the firm's site: bgandg.com/scyx . You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC